Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 4/20 | 0.54 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23146379 | 0.81 | CDC7 (0.59) | CDC7DBF4ALDH1A1HSD17B10HPGD | |
| SCHEMBL29670176 | 0.81 | CDC7 (0.59) | CDC7DBF4ALDH1A1HSD17B10HPGD | |
| SCHEMBL23146170 | 0.79 | CDC7 (0.63) | CDC7DBF4ALDH1A1HSD17B10MAPT | |
| SCHEMBL11698155 | 0.78 | CDC7 (0.59) | CDC7DBF4ALDH1A1HSD17B10MAPT | |
| SCHEMBL23980465 | 0.78 | ALDH1A1 (0.44) | ALDH1A1HSD17B10MAPTMEN1KMT2A | |
| SCHEMBL30260567 | 0.78 | ALDH1A1 (0.44) | ALDH1A1HSD17B10MAPTMEN1KMT2A | |
| SCHEMBL6487827 | 0.78 | CDC7 (0.61) | CDC7DBF4ALDH1A1HSD17B10HPGD | |
| SCHEMBL29715242 | 0.78 | CDC7 (0.61) | CDC7DBF4ALDH1A1HSD17B10HPGD | |
| SCHEMBL20073715 | 0.77 | GAA (0.44) | ALDH1A1HSD17B10MAPTMEN1KMT2A | |
| SCHEMBL29666414 | 0.76 | HTR2C (0.47) | ALDH1A1HSD17B10HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240840-B2 | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-04 | — | — | US | disclosed |
| CN-113227071-B | Amide-substituted heterocyclic compounds for the treatment of disorders associated with modulation of IL-12, IL-23 and/or IFN-alpha | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230020273-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230020273-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3873892-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | Bristol-Myers Squibb Company (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113227071-A | Amide-substituted heterocyclic compounds for the treatment of disorders associated with the modulation of IL-12, IL-23 and/or IFN-alpha | 百时美施贵宝公司 | 2021-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020273-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | TYK2, IFNG, JAK3 | CDC7 2376/4885DBF4 4344/4885ALDH1A1 4302/4885 |
| US-12240840-B2 | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha | TYK2, IFNG, JAK3 | CDC7 2376/4885DBF4 4344/4885ALDH1A1 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.